Orientations

Off-label vaccine use: explanatory note for countries

World Health Organization (WHO)

The document explains what off-label use of a vaccines is, why SAGE makes off-label recommendations and describes considerations for countries when using a vaccine off-label.  

Auteurs

Langues

  • Anglais

Année de publication

2024

Type

Orientations

Catégories

  • Vaccins et dispositifs d'administration

Maladies

  • Mpox

Organisations

  • Organisation Mondiale de la Santé (OMS)

Mpox-Policy

Cette ressource apparaît sur le Thème suivant:

Cette ressource est incluse dans le tableau suivant:

TitreAuteurAnnéeTypeLangue
Smallpox and mpox (orthopoxviruses): WHO position paperWorld Health Organization (WHO)2024GuidanceAnglais, Français
Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label useWorld Health Organization (WHO)2025PresentationAnglais
Off-label vaccine use: explanatory note for countriesWorld Health Organization (WHO)2024GuidanceAnglais
MVA-BN (‎Modified Vaccinia Ankara – Bavarian Nordic)‎ smallpox and mpox vaccine: Interim guidanceWorld Health Organization (WHO)2024GuidanceAnglais, Français
ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of ageEuropean Medicines Agency2024GuidanceAnglais
Regulatory & Policy Considerations for Mpox Vaccines in African CountriesWorld Health Organization (WHO), European Medicines Agency, Bavarian Nordic2025PresentationAnglais
LC16m8 (live-attenuated freeze-dried vaccinia) smallpox and mpox vaccine - Interim GuidanceWorld Health Organization (WHO)2025GuidanceAnglais, Français
Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak responseWorld Health Organization (WHO)2025GuidanceAnglais

Mpox-Policy-FR

Cette ressource est incluse dans le tableau suivant:

TitreAuteurAnnéeTypeLangue
Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label useWorld Health Organization (WHO)2025PresentationAnglais
Off-label vaccine use: explanatory note for countriesWorld Health Organization (WHO)2024GuidanceAnglais
Note de synthèse: position de l’OMS sur les vaccins contre la variole et la mpox (orthopoxvirus)World Health Organization (WHO)2024GuidanceFrançais, Anglais
Vaccin contre la variole et la mpox MVA-BN (‎Modified Vaccinia Ankara - Bavarian Nordic)‎ : directives provisoiresWorld Health Organization (WHO)2024GuidanceFrançais, Anglais
ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of ageEuropean Medicines Agency2024GuidanceAnglais
Regulatory & Policy Considerations for Mpox Vaccines in African CountriesWorld Health Organization (WHO), European Medicines Agency, Bavarian Nordic2025PresentationAnglais
Vaccin LC16m8 (‎vaccin lyophilisé vivant atténué)‎ contre la variole et la variole du singe : directives provisoiresWorld Health Organization (WHO)2025GuidanceFrançais, Anglais
Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak responseWorld Health Organization (WHO)2025GuidanceAnglais

Ajouté par: Géraldine Nemrod

Ajouté le: 2024-11-19 15:07:53

Consultations: 1126

Liens

Signaler un problème

Ajouter une ressource